RayzeBio, Inc. Common Stock
RYZB
RYZB was delisted on the 23rd of February, 2024.
0 hedge funds and large institutions have $0 invested in RayzeBio, Inc. Common Stock in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 106 closing their positions.
100% less funds holding
Funds holding: 107 → 0 (-107)
100% less funds holding in top 10
Funds holding in top 10: 18 → 0 (-18)
100% less capital invested
Capital invested by funds: $3.41B → $0 (-$3.41B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 106
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
-$413M |
| 2 |
VP
venBio Partners
San Francisco,
California
|
-$321M |
| 3 |
VVM
Versant Venture Management
San Francisco,
California
|
-$321M |
| 4 |
VA
VR Adviser
New York
|
-$251M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$216M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Legal & General Group
London,
United Kingdom
| – | -$120K | -1,930 | Closed |
|
|
PCM
102
PenderFund Capital Management
Vancouver,
British Columbia, Canada
| – | -$148K | -1,800 | Closed |
|
|
MLICM
103
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$73.4K | -1,181 | Closed |
|
|
TRCT
104
Tower Research Capital (TRC)
New York
| – | -$51.4K | -826 | Closed |
|
|
WTA
105
Washington Trust Advisors
Wellesley,
Massachusetts
| – | -$8.46K | -136 | Closed |
|
|
EC
106
EntryPoint Capital
New York
| – | -$6.09K | -98 | Closed |
|
RYZB Hedge Fund Activity: Q1 2024 in Review
0 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in RayzeBio, Inc. Common Stock (RYZB) for Q1 2024, worth a combined $0 — down 100% from $3.41B a quarter earlier.
Sellers outnumbered buyers: 106 funds closed out of RYZB and 0 opened new positions — a net loss of 106 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Viking Global Investors, exiting entirely with an estimated $413M sold.
- 0 institutional investors held RayzeBio, Inc. Common Stock (RYZB) as of Q1 2024, down from 107 in Q4 2023.
- Funds reported $0 of RayzeBio, Inc. Common Stock stock for Q1 2024, down 100% quarter-over-quarter.
- 0 funds opened new RayzeBio, Inc. Common Stock positions in Q1 2024 and 106 closed out, a net change of -106 holders.
- The largest RayzeBio, Inc. Common Stock seller in Q1 2024 was Viking Global Investors, an estimated $413M sold.
Based on aggregated 13F filings for Q1 2024.